Compare · CRON vs DFTX
CRON vs DFTX
Side-by-side comparison of Cronos Group Inc. (CRON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CRON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $6.03B, about 4.9x CRON ($1.22B).
- Over the past year, CRON is up 28.2% and DFTX is up 356.2% - DFTX leads by 328.0 points.
- DFTX has been more active in the news (15 items in the past 4 weeks vs 6 for CRON).
- CRON has more recent analyst coverage (11 ratings vs 7 for DFTX).
- Company
- Cronos Group Inc.
- Definium Therapeutics Inc.
- Price
- $3.32+3.11%
- $44.89-1.15%
- Market cap
- $1.22B
- $6.03B
- 1M return
- +21.39%
- +4.61%
- 1Y return
- +28.19%
- +356.20%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 15
- Recent ratings
- 11
- 7
Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Latest CRON
- SEC Form 4 filed by Director Garnick Murray R
- SEC Form 4 filed by Director Rudyk James Daniel
- SEC Form 4 filed by Director Adler Jason Marc
- Amendment: Cronos Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Cronos Group Inc.
- Cronos Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles
- Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
- Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada
- SEC Form 3 filed by new insider Broughton Darren Chester
Latest DFTX
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder